{"filing":{"accession_number":"0001121404-26-000008","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-07-30","report_date":"2026-06-30","primary_document":"a6kcoverpagepressreleaseq2.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/a6kcoverpagepressreleaseq2.htm"},"events":[{"id":21945,"run_id":19815,"accession_number":"0001121404-26-000008","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a quarterly earnings press release for Q2 2026 disclosing Sanofi's financial results, including net sales of €11,597 million (up 17.8% at CER), business EPS of €2.09 (up 33.3% at CER), and detailed segment performance across Pharma and Vaccines. The document explicitly states \"Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded\" and includes comprehensive financial tables, product-level sales commentary, and forward guidance. This is a material event affecting investor assessment of the registrant's operational and financial performance.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-07-30","form":"6-K","submitted_at":null,"items":[{"id":21729,"accession_number":"0001121404-26-000008","item_number":"EX-99.1","item_title":"pressreleaseq22026english.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a quarterly earnings press release for Q2 2026 disclosing Sanofi's financial results, including net sales of €11,597 million (up 17.8% at CER), business EPS of €2.09 (up 33.3% at CER), and detailed segment performance across Pharma and Vaccines. The document explicitly states \"Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded\" and includes comprehensive financial tables, product-level sales commentary, and forward guidance. This is a material event affecting investor assessment of the registrant's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:29:39.267800+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21729,"accession_number":"0001121404-26-000008","item_number":"EX-99.1","item_title":"pressreleaseq22026english.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a quarterly earnings press release for Q2 2026 disclosing Sanofi's financial results, including net sales of €11,597 million (up 17.8% at CER), business EPS of €2.09 (up 33.3% at CER), and detailed segment performance across Pharma and Vaccines. The document explicitly states \"Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded\" and includes comprehensive financial tables, product-level sales commentary, and forward guidance. This is a material event affecting investor assessment of the registrant's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:29:39.267800+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-07-30"}]}